Argent BioPharma Valuation
Is RGT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RGT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RGT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RGT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RGT?
Key metric: As RGT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RGT's PS Ratio? | |
|---|---|
| PS Ratio | 14.6x |
| Sales | AU$891.08k |
| Market Cap | AU$13.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 24x |
| Enterprise Value/EBITDA | -1.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RGT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.3x | ||
EOF Ecofibre | 0.5x | n/a | AU$15.4m |
EMD Emyria | 7.4x | n/a | AU$16.2m |
AVE Avecho Biotechnology | 18.7x | n/a | AU$6.3m |
IVX Invion | 2.8x | n/a | AU$14.3m |
RGT Argent BioPharma | 14.6x | n/a | AU$13.0m |
Price-To-Sales vs Peers: RGT is expensive based on its Price-To-Sales Ratio (14.6x) compared to the peer average (7.6x).
Price to Sales Ratio vs Industry
How does RGT's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price-To-Sales vs Industry: RGT is expensive based on its Price-To-Sales Ratio (14.6x) compared to the Australian Pharmaceuticals industry average (4.9x).
Price to Sales Ratio vs Fair Ratio
What is RGT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 14.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RGT's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Neuren Pharmaceuticals
AU$1.6b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$12.32
7D
-16.8%
1Y
-18.7%
AVITA Medical
US$343.1m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.97
7D
5.0%
1Y
16.4%
AVITA Medical
US$343.1m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.98
7D
5.0%
1Y
16.4%